Sarcomatoid RCC – molecular features and new opportunities for treatment

Sarcomatoid renal cell carcinoma (RCC) is difficult to treat and has long been associated with a poor prognosis. Also, the biology of sarcomatoid RCC has remained obscure. Scientists have tried to determine the molecular profile of sarcomatoid RCC and investigate different targeted therapies for genes such as TP53,┬áBAP1, cell cycle, and chromatin-remodelling genes. Investigation of […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Molecular genetics of renal cell carcinoma

Most renal cell carcinomas (RCC) are diagnosed from studying the cells from a biopsy under a microscope (histology findings), with and without the use of antibodies to check for certain proteins in the tumour tissue (immunohistochemical examination). RCC tumours are very heterogeneous – there are many subtypes of RCC which have different appearances under the […]

read more

Rational approaches to treatment duration with immunotherapy for kidney cancer

A recent review of the use of immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC) was published in European Urology Focus this month. The use of immune checkpoint inhibitors has revolutionised the treatment of metastatic RCC over recent years. However, the appropriate duration of treatment with immune checkpoint inhibitors, such as […]

read more

Long term survival after radiofrequency ablation for kidney cancer

A study published in the Journal of Vascular and Interventional Radiology looked at the long-term survival benefits from radiofrequency ablation (RFA) in patients with localised renal cell carcinoma (RCC). The outcomes of 100 patients with localised RCC (kidney cancer that has not spread) were looked at retrospectively. All patients had percutaneous radiofrequency ablation and were […]

read more

Immunotherapy combinations standard of care for advanced kidney cancer

In 2015, the standard treatment for most patients with advanced kidney cancer was a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) such as sunitinib or pazopanib for untreated patients, followed by a checkpoint inhibitor (PD-1 inhibitor) such as nivolumab for patients who fail treatment with a VEGF inhibitor. However, over the last several […]

read more

Individualised treatment plans improve outcomes for kidney cancer

Over the past couple of years there have been several approvals of new treatments and drug combinations for advanced/metastatic renal cell carcinoma (RCC) resulting in treatment plans that are tailored for the individual patient. Recent advances in the treatment of advanced/metastatic RCC include cabozantinib, nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib. Dr Ajjai Shivaram Alva, associate professor at […]

read more

Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients

Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have revolutionised the treatment for metastatic renal cell carcinoma (RCC). However, the most appropriate duration for immunotherapy treatment is not clear. In a recent analysis of the results from the phase III CheckMate 214 trial, all RCC patients randomised to receive the nivolumab/ipilimumab combination had longer […]

read more

Predictive biomarkers needed for combination treatments in kidney cancer

In this interview with OncLive, Dr Ulka Vaishampayan from Wayne State University in Detroit, USA discusses the immunotherapy combinations that have been approved for first line treatment of metastatic renal cell carcinoma (mRCC) over the past year or so, and the need to identify biomarkers that can guide treatment selection for these patients. The combination […]

read more

PARP inhibitors, vaccines and combination therapies for kidney cancer

In this interview with OncLive, professor Sumanta Kumar Pal from City of Hope Hospital in California discusses the potential of poly ADP ribose polymerase (PARP) inhibitors, chimeric antigen receptor (CAR)-based products, vaccines, and novel drug combinations for the treatment of metastatic renal cell carcinoma (mRCC). Results from the phase Ib/II TiNivo study of the combination […]

read more
Showing 1 to 10 of 545 results
  TOP